56 results about "VKORC1" patented technology

The invention discloses a specific primer, a liquid-phase chip and a method for SNP detection of CYP2C9 and VKORC1 genes. The liquid-phase chip comprises wild-type and mutable-type ASPE primer pairs and microspheres coated by a specific anti-tag sequence respectively, which are designed respectively aiming at each type of mutable loci, primers used for amplifying a CYP2C9 gene target sequence having CYP2C9*2, CYP2C9*3, CYP2C9*5 and CYP2C9*6SNP loci, and / or primers used for amplifying a VKORC1 gene target sequence having G1639A, G1173T and G3730A SNP loci. The liquid phase chip of the invention has a quite good signal-noise ratio, and the cross reaction does not happen between a designed probe and the anti-tag sequence basically; the ASPE primer designed by the invention has quite good specificity, and can accurately differentiate various types of mutable loci; and the detection method has the advantages that: a few steps are adopted, 7 types of SNP loci can be detected in one step, the operation is convenient, a lot of uncertain factors existing in a process of repeated operations can be avoided, and the detection accuracy is greatly improved.

The invention provides a warfarin individual anticoagulant pharmacogenomics detection kit suitable for Chinese population, which mainly comprises CYP2C9, VKORC1 and CYP4F2 related gene-type amplification primers, CYP2C9, VKORC1 and CYP4F2 related gene-type sequencing primers, a polymerase chain reaction (PCR) reagent and a sequencing reagent. The warfarin individual anticoagulant pharmacogenomicsdetection kit suitable for the Chinese population also can comprise a specification used for explaining a warfarin pharmacogenomics dose prediction model suitable for the Chinese population or / and a computer readable storage medium recording the warfarin pharmacogenomics dose prediction model suitable for the Chinese population. The warfarin pharmacogenomics detection kit provided by the invention is simple in preparation and is convenient in use. By adopting the kit, the warfarin anticoagulant therapy dose of Chinese patient population can be accurately estimated through detecting warfarin pharmacogenomics indexes, integrating clinical environmental factors and utilizing warfarin pharmacogenomics dose prediction model software suitable for the Chinese population, which is established by the invention.

The invention provides a kit for detecting SNP locus of a gene associated with individualized medication of warfarin and a PCR amplification method thereof. The kit comprises two forward primers and a reverse primer used for detecting SNP locus of a gene VKORC1(-1639G / A) and / or two forward primers and a reverse primer used for detecting SNP locus of a gene CYP2C9(1075A / C). The kit of the invention can realize the high-efficiency and high-pass detection of the SNP loci of VKORC1(-1639G / A) and CYP2C9(1075A / C), so that the quantized control on the amount of warfarin is achieved; furthermore, the method plays a certain role in prevention of thrombotic diseases, choice of anticoagulants, research and development of new anticoagulants and prognosis of thrombotic diseases.

Methods for developing an ontology of pharmacogenomics (PGx) relationships starting from a lexicon of key pharmacogenomic entities and a syntactic parse is described. The syntactic structure of PGx statements is used to systematically extract commonly occurring relationships and to map them to a common schema. In an embodiment, extracted relationships have a 70-87.7% precision and involve not only key PGx entities such as genes, drugs, and phenotypes (e.g., VKORC1, warfarin, clotting disorder), but also critical entities that are frequently modified by these key entities (e.g., VKORC1 polymorphism, warfarin response, clotting disorder treatment).

The invention provides a host cell containing a vector for expressing a functional recombinant human coagulation factor VII and a high-level expression method of the functional recombinant human coagulation factor VII, and aims at establishing an expression vector containing F VII, GGCX and VKORC1 recombinant nucleic acids and improving the g-carboxylation modification of the recombinant F VII by virtue of coordinated expression of the GGCX and the VKORC1. The host cell contains the F VII recombinant nucleic acid (human coagulation factor VII), depending on which the vitamin K is coded, a VKORC1 (mouse vitamin K epoxide reductase complex subunit 1) recombinant nucleic acid and a GGCX (mouse g glutamyl carboxylase) recombinant nucleic acid, as well as an insulator (4X) recombinant nucleic acid; the high-level expression method of the functional recombinant human coagulation factor VII comprises the steps of establishing an expression vector, mediating the expression vector into a DHFR deficient CHO animal cell by use of a lipidosome method and screening out positive clones by virtue of a DMEM culture medium, performing serum-free acclimation and culture on the host cell strain, purifying the h FVII recombinant protein by virtue of nickel ion affinity chromatography and performing SDS-PAGE and Westernblot detection, and finally, determining the procoagulant activity of the FVII recombinant protein according to the prothrombin time (PT).

The invention provides a preparation method of an electrochemical sensor for VKORC1-1639G> A gene polymorphism detection, first, amino-modified polyamide dendritic polymer PAMAM is used to process and functionalize hollow nano platinum to obtain a tPNPs-PAMAM composite material, the tPNPs-PAMAM composite material, a single strand DNA signal probe and fullerene nanoparticles are mixed to obtain a redox probe, and by layer by layer self-assembly of reductive graphene oxide tetraethylenepentamine, nano gold and avidin, biotinylated tetrahedral DNA capture probe is fixed, and then the electrochemical sensor for VKORC1-1639G> A gene polymorphism detection is prepared. The electrochemical sensor is successfully used for detection of single base mutation of VKORC1. The electrochemical sensor has the advantages of high sensitivity, strong specificity, rapid detection and convenience. The electrochemical sensor provides a new detection method for warfarin individualized medication.

The present invention relates to a host organism containing recombinant nucleic acids coding for the vitamin K reductase complex subunit 1 (VKORC1) and recombinant nucleic acids coding for a vitamin K dependent (VKD) protein, wherein both the recombinant VKORC1 and the recombinant VKD protein are expressed in said host organism. Further, the present invention relates to a cell culture system comprising cells which contain said recombinant nucleic acids and to methods for improving the productivity of recombinant VKD protein expression in a host organism being cultured in suitable systems.

The invention relates to a novel polypeptide vitamin K epoxide recycling polypeptide (VKORC1) as a target for coumarin and its derivatives. The invention further provides methods for identifying coumarin derivatives, and also claims VKORC1 polypeptides and VKORC1 nucleic acids containing a sequence abnormality associated with a VKORC1 associated deficiency such as warfarin resistance, wherein the VKORC1 polypeptides and VKORC1 nucleic acids can be used for diagnosing these deficiencies. Moreover, the invention relates to methods for identifying coumarin derivatives usable in pest control of rodents.